ArticleCEN case reports2019

Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.

Sami Alobaidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.